Agiomix BRCA panel uses the Next Generation Sequencing method to identify variations in the associated genes and help the patients determine their hereditary predisposition to developing cancer. Identifying these variations early is important to determine strategies for prevention, early detection and planning treatment if necessary.
Under OncoSeq® BRCA, screening is done for the below 15 genes to identify the cause of the disease:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MUTYH, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53.
Under OncoSeq® Colon, screening is done for the below 10 genes to identify the cause of the disease:
APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, STK11, TP53
Under OncoSeq® Repair, screening is done for the below 14 genes to identify the cause of the disease:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2 (Does not include MRE11A)
Under OncoSeq® Guard, screening is done for the below 2 genes to identify the cause of the disease:
Who should get OncoSeq® Suite Screening done?
- An individual who is diagnosed with the cancer
- When there is a family history of cancer
- When there is an increased risk of cancer
- When you are worried about the risk of cancer
- DNA in TE Buffer or Water
- Peripheral Blood in EDTA Tubes
Relevant Syndromes Covered:
Hereditary Breast and Ovarian Cancer Syndrome, Li-Fraumeni Syndrome, Cowden (PTEN) Hamartomas Syndrome, Peutz-Jeghers Syndrome, Hereditary Diffuse Gastric Cancer Syndrome
For more details about each panel and a complete list of syndromes, please contact us at 800 – GENOMICS (43666427)